{"count": 6, "results": [{"_id": "35112882", "pmid": 35112882, "pmcid": "PMC9245817", "title": "Cardiovascular Events and Long-Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVE-IT", "journal": "J Am Heart Assoc", "authors": ["Fordyce CB", "Giugliano RP", "Cannon CP", "Roe MT", "Sharma A", "Page C", "White JA", "Lokhnygina Y", "Braunwald E", "Blazing MA"], "date": "2022-02-15T00:00:00Z", "doi": "10.1161/JAHA.121.022733", "meta_date_publication": "2022 Feb 15", "meta_volume": "11", "meta_issue": "4", "meta_pages": "e022733", "score": 50230.953, "text_hl": "Using adjudicated end point data from the IMPROVE-IT (Improved Reduction of Outcomes: @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@Vytorin@@@ Efficacy International Trial) population with 7 years of follow-up, the data show that stable @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Acute_Coronary_Syndrome</m> @DISEASE_MESH:D054058 @@@acute coronary syndrome@@@ remain at risk of @DISEASE_Death_Sudden @DISEASE_MESH:D003645 @@@sudden death@@@ with a cumulative incidence of 2.47% during follow-up, with >70% of @DISEASE_Death_Sudden @DISEASE_MESH:D003645 @@@sudden deaths@@@ occurring late (>1 year) following @<m>DISEASE_Acute_Coronary_Syndrome</m> @DISEASE_MESH:D054058 @@@acute coronary syndrome@@@.", "citations": {"NLM": "Fordyce CB, Giugliano RP, Cannon CP, Roe MT, Sharma A, Page C, White JA, Lokhnygina Y, Braunwald E, Blazing MA. Cardiovascular Events and Long-Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVE-IT J Am Heart Assoc. 2022 Feb 15;11(4):e022733. PMID: 35112882", "BibTeX": "@article{35112882, title={Cardiovascular Events and Long-Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVE-IT}, author={Fordyce CB and Giugliano RP and Cannon CP and Roe MT and Sharma A and Page C and White JA and Lokhnygina Y and Braunwald E and Blazing MA}, journal={J Am Heart Assoc}, volume={11}, number={4}, pages={e022733}}"}}, {"_id": "26039521", "pmid": 26039521, "title": "Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.", "journal": "N Engl J Med", "authors": ["Cannon CP", "Blazing MA", "Giugliano RP", "McCagg A", "White JA", "Theroux P", "Darius H", "Lewis BS", "Ophuis TO", "Jukema JW", "De Ferrari GM", "Ruzyllo W", "De Lucca P", "Im K", "Bohula EA", "Reist C", "Wiviott SD", "Tershakovec AM", "Musliner TA", "Braunwald E", "Califf RM", "IMPROVE-IT Investigators"], "date": "2015-06-18T00:00:00Z", "doi": "10.1056/NEJMoa1410489", "meta_date_publication": "2015 Jun 18", "meta_volume": "372", "meta_issue": "25", "meta_pages": "2387-97", "score": 50074.824, "text_hl": "@CHEMICAL_Ezetimibe @CHEMICAL_MESH:D000069438 @@@Ezetimibe@@@ Added to Statin Therapy after @<m>DISEASE_Acute_Coronary_Syndrome</m> @DISEASE_MESH:D054058 @@@Acute Coronary Syndromes@@@.", "citations": {"NLM": "Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM, IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015 Jun 18;372(25):2387-97. PMID: 26039521", "BibTeX": "@article{26039521, title={Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.}, author={Cannon CP and Blazing MA and Giugliano RP and McCagg A and White JA and Theroux P and Darius H and Lewis BS and Ophuis TO and Jukema JW and De Ferrari GM and Ruzyllo W and De Lucca P and Im K and Bohula EA and Reist C and Wiviott SD and Tershakovec AM and Musliner TA and Braunwald E and Califf RM and IMPROVE-IT Investigators}, journal={N Engl J Med}, volume={372}, number={25}, pages={2387-97}}"}}, {"_id": "25912112", "pmid": 25912112, "title": "Simvastatin-ezetimibe combination therapy is associated with a lower rate of major adverse cardiac events in type 2 diabetics than high potency statins alone: A population-based dynamic cohort study.", "journal": "Int J Cardiol", "authors": ["Chang SH", "Wu LS", "Lee CH", "Kuo CT", "Liu JR", "Wen MS", "Chen WJ", "See LC", "Yeh YH"], "date": "2015-01-01T00:00:00Z", "doi": "10.1016/j.ijcard.2015.04.121", "meta_date_publication": "2015", "meta_volume": "190", "meta_issue": "", "meta_pages": "20-5", "score": 50066.84, "text_hl": "BACKGROUND: Recent trials have shown a reduction in the risk of @DISEASE_Epilepsy_Tonic_Clonic @DISEASE_MESH:D004830 @@@major@@@ adverse @DISEASE_Cardiovascular_Diseases @DISEASE_MESH:D002318 @@@cardiac events@@@ (@DISEASE_Cardiovascular_Diseases @DISEASE_MESH:D002318 @@@MACE@@@) with @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@simvastatin-ezetimibe@@@ therapy in @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Acute_Coronary_Syndrome</m> @DISEASE_MESH:D054058 @@@acute coronary syndrome@@@. ", "citations": {"NLM": "Chang SH, Wu LS, Lee CH, Kuo CT, Liu JR, Wen MS, Chen WJ, See LC, Yeh YH. Simvastatin-ezetimibe combination therapy is associated with a lower rate of major adverse cardiac events in type 2 diabetics than high potency statins alone: A population-based dynamic cohort study. Int J Cardiol. 2015;190():20-5. PMID: 25912112", "BibTeX": "@article{25912112, title={Simvastatin-ezetimibe combination therapy is associated with a lower rate of major adverse cardiac events in type 2 diabetics than high potency statins alone: A population-based dynamic cohort study.}, author={Chang SH and Wu LS and Lee CH and Kuo CT and Liu JR and Wen MS and Chen WJ and See LC and Yeh YH}, journal={Int J Cardiol}, volume={190}, pages={20-5}}"}}, {"_id": "31314050", "pmid": 31314050, "title": "Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial.", "journal": "JAMA Cardiol", "authors": ["Bach RG", "Cannon CP", "Giugliano RP", "White JA", "Lokhnygina Y", "Bohula EA", "Califf RM", "Braunwald E", "Blazing MA"], "date": "2019-09-01T00:00:00Z", "doi": "10.1001/jamacardio.2019.2306", "meta_date_publication": "2019 Sep 1", "meta_volume": "4", "meta_issue": "9", "meta_pages": "846-854", "score": 50065.14, "text_hl": "Effect of @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@Simvastatin-Ezetimibe@@@ Compared With @CHEMICAL_Simvastatin @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ Monotherapy After @<m>DISEASE_Acute_Coronary_Syndrome</m> @DISEASE_MESH:D054058 @@@Acute Coronary Syndrome@@@ Among @SPECIES_9606 @@@Patients@@@ 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial.", "citations": {"NLM": "Bach RG, Cannon CP, Giugliano RP, White JA, Lokhnygina Y, Bohula EA, Califf RM, Braunwald E, Blazing MA. Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2019 Sep 1;4(9):846-854. PMID: 31314050", "BibTeX": "@article{31314050, title={Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial.}, author={Bach RG and Cannon CP and Giugliano RP and White JA and Lokhnygina Y and Bohula EA and Califf RM and Braunwald E and Blazing MA}, journal={JAMA Cardiol}, volume={4}, number={9}, pages={846-854}}"}}, {"_id": "29263150", "pmid": 29263150, "title": "Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).", "journal": "Circulation", "authors": ["Giugliano RP", "Cannon CP", "Blazing MA", "Nicolau JC", "Corbalán R", "Špinar J", "Park JG", "White JA", "Bohula EA", "Braunwald E", "IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators"], "date": "2018-04-10T00:00:00Z", "doi": "10.1161/CIRCULATIONAHA.117.030950", "meta_date_publication": "2018 Apr 10", "meta_volume": "137", "meta_issue": "15", "meta_pages": "1571-1582", "score": 50062.28, "text_hl": "METHODS: In IMPROVE-IT (Improved Reduction of Outcomes: @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@Vytorin@@@ Efficacy International Trial), 18 144 @SPECIES_9606 @@@patients@@@ after @<m>DISEASE_Acute_Coronary_Syndrome</m> @DISEASE_MESH:D054058 @@@acute coronary syndrome@@@ with low-density lipoprotein cholesterol 50 to 125 mg/dL were randomized to 40 mg @CHEMICAL_Ezetimibe @CHEMICAL_MESH:D000069438 @@@ezetimibe@@@/@CHEMICAL_Simvastatin @CHEMICAL_MESH:D019821 @@@simvastatin@@@ (@<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@E/S@@@) or 40 mg placebo/@CHEMICAL_Simvastatin @CHEMICAL_MESH:D019821 @@@simvastatin@@@. ", "citations": {"NLM": "Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalán R, Špinar J, Park JG, White JA, Bohula EA, Braunwald E, IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018 Apr 10;137(15):1571-1582. PMID: 29263150", "BibTeX": "@article{29263150, title={Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).}, author={Giugliano RP and Cannon CP and Blazing MA and Nicolau JC and Corbalán R and Špinar J and Park JG and White JA and Bohula EA and Braunwald E and IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators}, journal={Circulation}, volume={137}, number={15}, pages={1571-1582}}"}}, {"_id": "18266852", "pmid": 18266852, "title": "Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study.", "journal": "Int J Clin Pract", "authors": ["Reckless JP", "Henry P", "Pomykaj T", "Lim ST", "Massaad R", "Vandormael K", "Johnson-Levonas AO", "Lis K", "Brudi P", "Allen C"], "date": "2008-04-01T00:00:00Z", "doi": "10.1111/j.1742-1241.2008.01697.x", "meta_date_publication": "2008 Apr", "meta_volume": "62", "meta_issue": "4", "meta_pages": "539-54", "score": 50060.324, "text_hl": "@<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@Eze/Simva@@@ was generally well tolerated, with a safety profile similar to statin. ", "citations": {"NLM": "Reckless JP, Henry P, Pomykaj T, Lim ST, Massaad R, Vandormael K, Johnson-Levonas AO, Lis K, Brudi P, Allen C. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. Int J Clin Pract. 2008 Apr;62(4):539-54. PMID: 18266852", "BibTeX": "@article{18266852, title={Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study.}, author={Reckless JP and Henry P and Pomykaj T and Lim ST and Massaad R and Vandormael K and Johnson-Levonas AO and Lis K and Brudi P and Allen C}, journal={Int J Clin Pract}, volume={62}, number={4}, pages={539-54}}"}}]}